Fintel reports that on June 7, 2023, Piper Sandler upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Overweight .
Analyst Price Forecast Suggests 8.03% Downside
As of June 2, 2023, the average one-year price target for Glaukos is 59.61. The forecasts range from a low of 44.44 to a high of $74.55. The average price target represents a decrease of 8.03% from its latest reported closing price of 64.82.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Glaukos is 315MM, an increase of 8.84%. The projected annual non-GAAP EPS is -1.75.
What is the Fund Sentiment?
There are 472 funds or institutions reporting positions in Glaukos. This is a decrease of 22 owner(s) or 4.45% in the last quarter. Average portfolio weight of all funds dedicated to GKOS is 0.17%, an increase of 8.08%. Total shares owned by institutions increased in the last three months by 0.00% to 56,539K shares. 
The put/call ratio of GKOS is 0.35, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 4,685K shares representing 9.72% ownership of the company. In it's prior filing, the firm reported owning 4,386K shares, representing an increase of 6.38%. The firm decreased its portfolio allocation in GKOS by 82.91% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 3,480K shares representing 7.22% ownership of the company. In it's prior filing, the firm reported owning 3,535K shares, representing a decrease of 1.59%. The firm increased its portfolio allocation in GKOS by 9.70% over the last quarter.
Brown Capital Management holds 2,905K shares representing 6.03% ownership of the company. In it's prior filing, the firm reported owning 2,713K shares, representing an increase of 6.60%. The firm increased its portfolio allocation in GKOS by 10.97% over the last quarter.
Artisan Partners Limited Partnership holds 1,875K shares representing 3.89% ownership of the company. In it's prior filing, the firm reported owning 1,905K shares, representing a decrease of 1.57%. The firm increased its portfolio allocation in GKOS by 5.05% over the last quarter.
Braidwell holds 1,807K shares representing 3.75% ownership of the company. In it's prior filing, the firm reported owning 1,662K shares, representing an increase of 8.01%. The firm increased its portfolio allocation in GKOS by 22.72% over the last quarter.
Glaukos Background Information
(This description is provided by the company.)
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
